Functional Deficits in nNOS\textsubscript{m}-Deficient Skeletal Muscle: Myopathy in nOS Knockout Mice

Justin M. Percival\textsuperscript{1,}\textsuperscript{*}, Kendra N. E. Anderson\textsuperscript{1}, Paul Gregorevic\textsuperscript{2,4,}\textsuperscript{a}, Jeffrey S. Chamberlain\textsuperscript{2,3,4}, Stanley C. Froehner\textsuperscript{1,4}

1 Department of Physiology and Biophysics, University of Washington, Seattle, Washington, United States of America, 2 Department of Neurology, University of Washington, Seattle, Washington, United States of America, 3 Department of Biochemistry, University of Washington, Seattle, Washington, United States of America, 4 Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, Washington, United States of America

Abstract

Skeletal muscle nNOS\textsubscript{m} (neuronal nitric oxide synthase mu) localizes to the sarcolemma through interaction with the dystrophin-associated glycoprotein (DAG) complex, where it synthesizes nitric oxide (NO). Disruption of the DAG complex occurs in dystrophinopathies and sarcoglycanopathies, two genetically distinct classes of muscular dystrophy characterized by progressive loss of muscle mass, muscle weakness and increased fatigability. DAG complex instability leads to mislocalization and downregulation of nNOS\textsubscript{m} but this is thought to play a minor role in disease pathogenesis. This view persists without knowledge of the role of nNOS in skeletal muscle contractile function \textit{in vivo} and has influenced gene therapy approaches to dystrophinopathy, the majority of which do not restore sarcolemmal nNOS\textsubscript{m}. We address this knowledge gap by evaluating skeletal muscle function in nNOS knockout (KN1) mice using an \textit{in situ} approach, in which the muscle is maintained in its normal physiological environment. nNOS-deficiency caused reductions in skeletal muscle bulk and maximum tetanic force production in male mice only. Furthermore, nNOS-deficient muscles from both male and female mice exhibited increased susceptibility to contraction-induced fatigue. These data suggest that aberrant nNOS\textsubscript{m} signaling can negatively impact three important clinical features of dystrophinopathies and sarcoglycanopathies: maintenance of muscle bulk, force generation and fatigability. Our study suggests that restoration of sarcolemmal nNOS\textsubscript{m} expression in dystrophic muscles may be more important than previously appreciated and that it should be a feature of any fully effective gene therapy-based intervention.

Citation: Percival JM, Anderson KNE, Gregorevic P, Chamberlain JS, Froehner SC (2008) Functional Deficits in nNOS\textsubscript{m}-Deficient Skeletal Muscle: Myopathy in nOS Knockout Mice. PLoS ONE 3(10): e3387. doi:10.1371/journal.pone.0003387

Editor: Antoni L. Andreu, Hospital Vall d’Hebron, Spain

Received July 18, 2008; Accepted September 12, 2008; Published October 13, 2008

Copyright: © 2008 Percival et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by NIH grants NS046788 and NS33145 (S.C.F.), NIH grant U54 HD047175 (S.C.F. and J.S.C.), a Parent Project for Muscular Dystrophy Research Fellowship (J.M.P) and a MDA Development Grant (J.M.P).

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: justinp2@u.washington.edu

\textsuperscript{a} Current address: Baker Heart Research Institute, Melbourne, Australia

Introduction

Nitric oxide (NO) is a versatile signaling molecule in skeletal muscle and is synthesized from oxygen and L-arginine by muscle-specific neuronal nitric oxide synthase mu (nNOS\textsubscript{m}) [1,2]. Functions of NO in muscle include: attenuation of muscle force generation and regulation of appropriate blood and oxygen delivery to active muscles during exercise [1,3–7]. However \textit{in vitro} studies of the role of nitric oxide in contractile function of excised muscles in perfusion baths have generated conflicting results. NO has been reported to increase force-generating capacity of skeletal muscle in some studies and decrease it in others [1,3–5]. This has led to questioning of the physiological relevance of these \textit{in vitro} studies [5]. These data suggest that the effects of nNOS on the force-generating capacity of muscle \textit{in vivo} remain to be determined.

Particular interest in nNOS\textsubscript{m} function in skeletal muscle arises from studies of human muscular dystrophies, nNOS\textsubscript{m} is localized to the sarcolemma by interaction with the dystrophin-associated glycoprotein (DAG) complex [8,9]. Disruption of the DAG complex results in decreased nNOS\textsubscript{m} expression and aberrant localization. DAG complex disruption occurs in several distinct dystrophies, including Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy and Limb Girdle Muscular Dystrophies (LGMD) 2C, 2D and 2E [8,10,11]. These muscle diseases vary in severity and are characterized by progressive loss of muscle bulk, weakness and increased susceptibility to fatigue. Each disease is characterized by defects in nNOS\textsubscript{m} expression and/or targeting. Indeed, DMD patients exhibit defective inhibition of vasoconstriction during exercise causing functional muscle ischemia that may exacerbate dystrophic muscle damage [12,13]. These studies suggest that loss of nNOS\textsubscript{m} may contribute to disease pathogenesis.

Although aberrant nNOS\textsubscript{m} localization and expression is a feature of the pathology of DMD, BMD and several LGMDs, it is not known whether the loss of nNOS\textsubscript{m} can cause contractile deficits in normal or dystrophic muscle \textit{in vivo}. Indeed, \textit{in vitro} studies of NO regulation of muscle contractility suggest that nNOS\textsubscript{m}-deficiency may actually enhance the force generating capacity of skeletal muscle [3,4]. This thinking has influenced the development of gene-therapy based therapeutic approaches to treating dystrophin-deficient muscles of DMD patients. Viral-mediated delivery of micro- or mini-dystrophin constructs substantially improves dystrophic pathology without restoring nNOS\textsubscript{m} expression at the...
sarclemma in the mdx mouse model of DMD [30,31]. Whether this is a significant limitation of the gene-therapy-based approach remains to be established. It could be a significant limitation if \( \text{nNOS}^\text{null} \)-deficient skeletal muscles exhibit functional deficits \textit{in vivo}.

In order to determine if the absence of \( \text{nNOS}^\text{null} \) negatively impacts skeletal muscle function, we evaluated the force-generating capacity \textit{in situ} of tibialis anterior (TA) muscles from \( \text{nNOS}^\text{null} \) knockout (KN1) mice. Given the reported effects of \( \text{nNOS}^\text{null} \) on blood supply during exercise, it was important to use an \textit{in situ} approach where the TA muscle was maintained in the most physiologically relevant state with normal vascularization. Unexpectedly, \( \text{nNOS}^\text{null} \)-deficient muscles from male mice were smaller in mass and generated significantly lower maximum isometric force compared with littermate controls. Moreover, muscles from both male and female mice lacking \( \text{nNOS}^\text{null} \) show increased susceptibility to fatigue compared with controls. In contrast to previous \textit{in vitro} studies, our data suggest that \( \text{nNOS}^\text{null} \)-deficiency results in reduced force-generating capacity and that NO is necessary for sustained muscle contractility. These data also suggest the possibility that mini- and micro-dystrophins capable of restoring sarclemmal \( \text{nNOS}^\text{null} \) expression may be more effective at reversing the functional deficits of dystrophic skeletal muscle. The combination of reduced bulk and impaired contractile function lead us to conclude that \( \text{nNOS}^\text{null} \)-deficient muscles are myopathic and that aberrant \( \text{nNOS}^\text{null} \) expression could contribute to functional deficits, especially increased susceptibility to fatigue, in DMD, BMD and LGMD 2C, 2D and 2E. We propose that the \( \text{NOS1} \) gene be considered a novel candidate for skeletal muscle myopathies.

**Results**

**Sex-Specific Decrease in Skeletal Muscle Bulk of nNOS-Deficient Mice**

\textit{Prima facie}, the most striking phenotypic characteristic of the \( \text{nNOS}^\text{null} \) mutant KN1 mice was the reduced body mass of males. Wild type males were on average 6 g heavier than their sex- and age-matched KN1 littermates (Figure 1A). Heterozygous mice appeared similar to wild type mice (data not shown). The well-established sexual dimorphism in body weight was evident from the significantly larger body masses of wild type males relative to wild type females. In contrast, the absence of \( \text{nNOS}^\text{null} \) did not impact the body mass of KN1 females (Figure 1A). Male mice are unable to achieve normal size in the absence of \( \text{nNOS}^\text{null} \).

Since, skeletal muscle mass accounts for approximately 40–50% of the total body mass of a normal male 8 week old mouse, reductions in skeletal muscle weight could account for the decreased size of the KN1 males. In order to determine the effect of \( \text{nNOS}^\text{null} \)-deficiency on muscle mass, the wet weights of two hindlimb muscles, the tibialis anterior (a predominantly fast twitch muscle) and soleus muscles (a predominantly slow twitch muscle), were measured. The masses of both the TA (Figure 1B) and soleus muscles (Figure 1C) were significantly decreased in male \( \text{nNOS}^\text{null} \) mutant mice only, compared with wild type male littermates. Mass reduction occurs in skeletal muscles with different fiber compositions, and therefore could reasonably account for the reduced body mass. In contrast, in female mice, the masses of both TA and soleus muscle were not significantly affected by the absence of \( \text{nNOS}^\text{null} \) (Figure 1B and 1C, respectively). Together, these data suggest the possibility that \( \text{nNOS} \) can act as a sex-specific regulator of skeletal muscle mass in mice.

**Decreased Maximum Tetanic Force-Generating Capacity of nNOS-Mutant Deficient Skeletal Muscle**

The amount of contractile force or tension a given skeletal muscle generates is generally proportional to the mass and length of the muscle itself. Given the reduced TA muscle bulk in male KN1 mice, we tested whether the maximum tetanic force-generating capacity of \( \text{nNOS}^\text{null} \)-deficient TA muscles was also decreased (Figure 2). Maximum tetanic force was significantly
Susceptibility to Contraction-Induced Fatigue

We then tested the hypothesis that nNOS deficiency impacts sustained force generation during muscle activity, i.e., the absence of nNOS may decrease resistance to exercise-induced fatigue. In order to test this possibility, TA muscles from KN1 mice were subjected to a simulated exercise protocol in situ (see Methods). Representative data from wild type and KN1 TA muscles are shown in Figure 3A and the averages are presented in 3B. After 40 s of simulated exercise, nNOS-deficient muscles begin to show deficits in force production (Figure 3A). By the end of the exercise protocol, the force-generating capacity of KN1 muscle had declined to a significantly lower force plateau (averaging 45.5±4.4%) compared with littermate controls (57.8±1.7%), (Figure 3B). Note that the trace shown exhibited near normal recovery. These data highlight a marked increase in fatigability of nNOS-deficient skeletal muscle. The time taken to fatigue, as represented by the time constant $t$, is not significantly different between nNOS-deficient TA muscles and controls (Figure 3B). After a 1 minute recovery period, KN1 muscles remain unable to generate normal levels of force compared with controls (Figure 3B). At 5 minutes post-exercise, nNOS-deficient muscles exhibit a full recovery (Figure 3B). Both male and female KN1 TA muscles showed similar enhanced susceptibility to exercise-induced fatigue (data not shown). It is important to note that susceptibility to fatigue was not simply a consequence of reduced muscle mass. TA masses from wild type female mice, male KN1 and female KN1 mice did not differ significantly (Figure 1B), but only nNOS-deficient TAs were more fatigable. These data highlight a novel role for nNOS in regulating sustained force generation during muscle activity.

Next, we addressed potential mechanism(s) of decreased fatigue resistance in nNOS-deficient skeletal muscle. We hypothesized...
that susceptibility to fatigue could be due to increased numbers of fast twitch fibers and fewer slow twitch fibers. Fast twitch fibers have a more glycolytic metabolism and thus fatigue more easily than slow twitch myofibers. A greater proportion of fast twitch fibers would decrease the time taken for the muscle to reach peak twitch tension (\(P_t\)) and shorten the relaxation phase. The twitch responses of nNOS-deficient muscles to a single threshold stimulus are shown in Table 1. Peak twitch force (\(P_t\)) was significantly reduced in KN1 males compared with controls. Despite this decrease, nNOS-deficient muscles did not exhibit any intrinsic weakness, because specific twitch force (\(sP_t\), [\(P_t\] normalized for cross sectional area]) did not differ from littermate controls (Table 1). However, in contrast to male KN1 muscle, \(P_t\) was unaffected by the absence of nNOS in female mice (Table 1). KN1 male mice exhibit a sex-specific decrease in \(P_t\), paralleling the decreased TA muscle mass and maximum isometric force deficit. The loss of nNOS from skeletal muscle had no significant impact on the time to reach peak tension and the time between maximum and half-maximum force production during the relaxation phase of the twitch (Table 1). The absence of significant difference in the time of the contraction and relaxation phase of the twitch suggest that there is no gross change in the fiber composition of the TA muscle and argue against a fiber type shift as a mechanism for the increased fatigability of nNOS-deficient muscle.

An alternative possibility was that the decreased resistance to fatigue in KN1 skeletal muscle was caused by an increase in the TA muscle’s susceptibility to contraction-induced injury. Therefore we tested whether nNOS-deficiency impacts resistance to contraction-induced injury in situ by subjecting TA muscles to a series of consecutive lengthening contractions of progressively increasing strain (Figure 4). We observed no significant difference in resistance to contraction-induced injury between wild type and nNOS-deficient TA muscles over a wide range of strains...
exercise is unlikely to be due to an increased predisposition to susceptibility of the TA to contraction-induced injury. The generating capacity of skeletal muscle. In the absence of nNOS, these data are not consistent with our findings act as an inhibitor or attenuator of muscle contractility. However, greater force output [3,4]. Thus, nitric oxide is widely understood to impairing vasoregulatory mechanisms. This emphasizes the importance of considering gender when experimentally assessing nNOS function. Our data suggest that nNOS is an important regulator of skeletal muscle size and contractile performance. One of the key features of nNOS-normal skeletal muscle is increased susceptibility to fatigue, arguably the most significant new finding of the present study. The force generated by nNOS-normal-deficient muscles during simulated exercise plateau at a significantly lower level than controls (Figure 3B). Recovery appears to occur more gradually in KN1 mice; however there is full restoration of force-generating capacity after a five minute rest period. In order to address potential mechanisms of decreased resistance to fatigue in KN1 mice, we looked for functional evidence of increased numbers of fast twitch fibers in KN1 TA muscle (Table 1). Fast twitch fibers are more easily fatigued than slow twitch fibers. Contraction and relaxation times of single muscle twitches were unaffected by the absence of nNOS, arguing that increased fatigability was not due to alterations in the ratio of fast to slow twitch fibers. nNOS-deficient NO plays an important role in maintaining normal blood supply during exercise by overriding α-adrenergic receptor-mediated vasoconstriction [6,7]. Impaired blood and oxygen delivery to the vascular beds of active muscles can result in repeated muscle exposure to functional ischemia [12]. Therefore we speculate that decreased muscle oxygenation could account, at least in part, for the susceptibility to fatigue of nNOS-deficient TA muscles. Additional evidence to support this possibility comes from dog studies in vivo where pharmacological inhibition of nitric oxide synthesis was proposed to cause fatigue by mismatching blood supply with demand in contracting skeletal muscles [18]. Muscle fatigue is a complex physiological process that can occur by many different mechanisms, further studies are required to address the exact mechanism(s) by which nNOS-deficiency results in increased susceptibility of skeletal muscle to fatigue. At present, nNOS deficiency does not appear to increase fatigability by significantly altering TA muscle fiber type composition, but may do so through impaired vasoregulatory mechanisms.

NO has been previously suggested to be an inhibitory of the force-generating capacity of skeletal muscle. In in vivo bath studies on excised muscles, the pharmacological inhibition of NO results in greater force output [3,4]. Thus, nitric oxide is widely understood to act as an inhibitor or attenuator of muscle contractility. However, these data are not consistent with our findings in vivo. We find that the absence of nNOS is associated with decreased maximal force-generating capacity in males. This is most likely due to decreased muscle mass and not due to defects in the contractile apparatus function; because specific force (sP) was unchanged (Figure 2B).

Similarly, the mass and force-generating capacity of female TA are unaffected by the absence of nNOS; therefore the differences between male and female force maximal force generation are likely due to differential impact on muscle mass. Also, inconsistent with the thesis that NO attenuates muscle function, we found that force frequency curves were unaffected by the loss of nNOS and the maximum force-generating properties of female muscle were unaffected by the loss of nNOS. In our view, the most likely explanation of the conflicting reports on the impact of NO on contractility is provided by the different experimental approaches employed. We used an in situ approach where the TA muscle is kept in the most physiologically relevant environment possible, within normal physiological temperature range, with intact motor neuron innervation and vasculature [17]. This is very important for evaluating nNOS function in muscle due to its known vasoregulatory role. We also circumvented the limitations of pharmacological inhibition of NO by using the KN1 mouse to specifically inactivate nNOS. Our view is supported by a recent study questioning the physiological relevance of studies designed to address the role of NO in muscle contraction that were conducted on excised muscles in physiological baths in vivo [5]. It was reported that regulation of muscle contractile function by nNOS depended dramatically on oxygen concentration [5]. At non-physiological oxygen concentrations, such as those found in excised in vivo muscle preparations, NO inhibited muscle contractility. Conversely, at low physiological oxygen tensions resembling those found in muscle tissue, NO increased the force-generating capacity of skeletal muscle [5]. Our finding that nNOS deficiency results in force loss in situ is consistent with in vitro studies performed under physiological oxygen conditions. Therefore, our in situ methods presumably maintain more physiologically relevant concentrations of oxygen in muscle tissue. In summary, these data suggest that nNOS-derived NO is necessary for maximal force-generating capacity of muscle in vivo and that nNOS plays an important role in the contractile performance of skeletal muscle. Furthermore, these results are consistent with a role of both oxygen and NO in coordinated regulation of the force-generating capacity of skeletal muscle.

The impact of nNOS-deficiency on muscle contractility has implications for two classes of muscle disease: metabolic myopathies and muscular dystrophies. Skeletal muscle fatigue is a common cause of weakness in human myopathies that result from congenital defects in energy metabolism [18]. These muscle diseases often elude diagnosis since symptoms occur predominantly or exclusively during exercise. Often symptoms are simply attributed to a lack of fitness [18]. Since the skeletal muscle phenotype of KN1 mice is consistent with that of human metabolic myopathies, the NOSI gene may be a novel candidate gene for this class of skeletal muscle disease. The deficiencies in nNOS-deficient skeletal muscle are also especially relevant to two types of muscular dystrophy, dystrophinopathies (DMD and BMD) and sarcoglycanopathies (LGMD 2C, LGMD 2D and LGMD 2E), two genetically distinct classes of muscular dystrophy where skeletal muscle nNOS expression and localization is dysregulated as a secondary consequence of the disruption of the DAG complex [8,10,11,19]. nNOS expression is undetectable in cytoplasmic or plasma membrane fractions from DMD patient biopsies [19]. Aberrant nNOS activity may contribute to the pathogenesis in DMD and LGMD by impairing blood flow in active muscles resulting in ischemia [6,7]. Indeed, increased NO bioavailability in mouse models of DMD (mdx mice) and LGMD2D (α-sarcoglycan null mice) substantially improves the pathology of dystrophic skeletal muscle tissue [20-22]. Our data suggest that specific characteristics of dystrophic pathology, including the inability to maintain muscle bulk, inherent muscle
weakness and susceptibility to fatigue may be attributable, at least in part, to defects in nNOS signaling. Our data also raise the intriguing possibility that loss of nNOSp in male patients than in female patients.

The pervasive inherent weakness of dystrophin-deficient muscle is due to both increased susceptibility to injury by lengthening contraction and fatigue [23–26]. The impaired performance of α- and γ-sarcoglycan-deficient skeletal muscles is also due, at least in part, to increased susceptibility to fatigue, but not contraction-induced injury [26–29]. Our data argue against a role for aberrant nNOSp expression contributing to increased susceptibility to contraction-induced injury, but do suggest the possibility that dysregulation of nNOS signaling provides a mechanism for muscle activity-induced fatigue, a contributing factor to the impaired contractile performance of human and murine dystrophic muscle [23–29]. These findings make nNOS signaling pathways relevant to therapeutic approaches to muscular dystrophy.

Therapeutic approaches to treating muscular dystrophies must address the progressive loss of muscle mass and extreme muscle weakness. The ideal method to do this is to replace the defective gene with a wild type copy using gene or cell therapy based approaches [14]. However, in the case of gene therapy of DMD, this is not currently possible because dystrophin is too large to be packaged into adeno-associated viral vectors. This has led to replacement strategies that involve viral vector-mediated delivery of truncated “designer dystrophin” constructs in DMD [14]. These micro- and mini-dystrophins cause substantial improvements, but do not fully restore the dystrophic pathology and muscle function in mdx mice. Importantly, these mutant dystrophins do not restore nNOSp [14]. Although the substantial improvement of dystrophic muscle function by mini- and micro-dystrophin suggests a minor role for nNOS in mdx pathology; the evaluation of fatigue is rarely, if ever, assayed in treated muscles despite reports of fatigue in both mice and patients [23–25]. Furthermore, mdx mice exhibit increased muscle mass, in contrast to Duchenne patients who suffer progressive loss of muscle mass. The present study suggests that the ability to restore nNOSp would likely confer additional important functionality to the designer dystrophins. These data strongly argue that the restoration of sarcolemmal nNOSp in dystrophic muscle may be more important than previously appreciated.

Materials and Methods

nNOS-Deficient Mice

B6.129S1-Nos1mpv/J mice purchased from The Jackson Laboratory, ME, USA were used to establish a colony. These mice are commonly known as nNOS knockout or KN1 mice and were generated by targeted disruption of exon 2 of the NOS1 gene [29]. Exon 2 encodes the PDZ domain of nNOSα and muscle-specific nNOSp; therefore, the skeletal muscles of KN1 mice lack nNOSp. All comparisons are made between sex- and age-matched littermates.

In Situ Contractile Function Analyses

All experimental procedures performed on mice were approved by the Institutional Animal Care and Use Committee of the University of Washington. We performed in situ analysis of TA muscle function with modifications as described previously [17]. This approach allows for measurement of contractile properties without removing the muscle from its natural environment, thereby maintaining normal vasoregulation and innervation. Eight week old mice were anesthetized with intraperitoneal injections of 2,2,2, tribromoethanol (Sigma, St Louis, MO). Mouse hindlimbs were shaved and the distal TA tendon of the tibialis anterior (TA) muscle was surgically isolated via a skin incision on the anterior surface of the lower hindlimb. The mouse was positioned on a 37°C heated platform in order to restrain the knee joint and the distal tendon was attached to the lever arm of a servomotor (Model 305B-LR, Aurora Scientific, ON, Canada). The exposed surface of the muscle was kept moist by frequent application of prewarmed isotonic saline. The TA muscle was stimulated by electrical trigger of the peroneal nerve using two needle electrodes. The muscle was adjusted to an optimum length (L0) that produced the maximum twitch force (Pt). Then, the time to reach peak tension (TPT) during the contraction phase of the twitch, and the half-relaxation time (HRT), the time between maximum and half-maximum force during the relaxation phase of the twitch were recorded. While held at L0, the TA was stimulated every two minutes at increasing frequencies (5 to 200 Hz) to generate force-frequency curves. Maximal tetanic force (Pt) generation was typically achieved at 200 Hz. After the completion of testing, both L0 and TA mass were recorded and used to normalize Pt and P0 for TA muscle size and calculate specific twitch (sPt) or specific tetanic (sP0) force. The first hindlimb was used for testing resistance to exercise-induced fatigue, while the second was used to test susceptibility to contraction-induced injury.

Resistance to Exercise-Induced Fatigue

To test the capacity of muscle to sustain force output, TA muscles were subjected to a series of repeated contractions to simulate exercise and cause fatigue. Muscles were subject to maximal stimulation (40 V, 200 Hz) at 2 s intervals for 4 minutes. Maximum isometric force production was recorded every 2 s. Recovery from fatigue was assessed by recording P0 at 1 minute and 5 minutes after the completion of the fatigue period. Exponential curves (y = Ae^−t/τ) were fitted to the 4 minute fatigue period with Igor Pro 5 software (Wavemetrics, OR). The time constant τ (reflecting the timecourse of fatigue in seconds where a larger τ value represents a slower rate of fatigue) and the force plateau (the asymptote of the exponential curve) were calculated from these curves.

Contraction-Induced Injury

The resistance of muscles to contraction-induced injury was assessed by subjecting TA muscles to a series of consecutive lengthening contractions of progressively increased strain. Strain is the percentage increase in length beyond the optimal muscle length L0. Muscles were maximally stimulated (4 V, 200 Hz) for 150 ms at fixed length to achieve maximal isometric tension, immediately followed by 200 ms of stimulation during the application of a length change ranging from 0 to 45% beyond L0. Strain was applied at the rate of 2 fiber lengths/s. Lengthening contractions were performed at 30 s intervals to minimize the impact of fatigue on force-generating capacity. The maximum tetanic force generated immediately prior to the initiation of the subsequent lengthening contraction was recorded and normalized. At the conclusion of contractile function analysis, animals were sacrificed and the tibialis anterior and soleus muscles were rapidly excised and weighed.

Statistical Analyses

The number of animals of each sex and genotype analyzed for each experimental condition are given in the figure legends. All values are reported as mean±SEM. Two way univariate analysis of variance (ANOVA) was used to determine the statistical significance of the effects of gender and genotype on experimental measures using SPSS software (SPSS Inc.). For all other comparisons, values were compared using unpaired Student’s t-
tests using Microsoft® Excel 2007 software. p values less than 0.05 were considered significant.

Acknowledgments

The authors wish to thank Dr Kimberley Craven for critical reading of the manuscript and Dr Glen Banks for excellent technical assistance.

References

1. Stamler JS, Meissner G (2001) Physiology of nitric oxide in skeletal muscle. Physiol Rev 81: 209–237.
2. Silvagno F, Xia H, Bredt DS (1996) Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. J Biol Chem 271: 11204–11208.
3. Kobilka B, Reid MB, Reid DS, Stamler JS (1994) Nitric oxide in skeletal muscle. Nature 372: 546–548.
4. Reid MB, Kobilka B, Reid DS, Stamler JS (1998) Nitric oxide modifies excitation-contraction coupling in the diaphragm. Comp Biochem Physiol A Mol Integr Physiol 19: 211–218.
5. Eu JP, Hare JM, Hess DT, Shaf M, Sun J, et al. (2003) Concerted regulation of skeletal muscle contractility by oxygen tension and endogenous nitric oxide. Proc Natl Acad Sci U S A 100: 15229–15234.
6. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, et al. (1998) Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 95: 15890–15895.
7. Thomas GD, Shaf PW, Yuanna DS, Frohner SC, Adams ME (2003) Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcomemal localization of neuronal nitric oxide synthase. Circ Res 92: 554–560.
8. Brenman JE, Chao DS, Xia H, Aldage K, Bredt DS (1995) Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82: 743–752.
9. Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, et al. (1996) Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha-syntrophin mediated by PDZ domains. Cell 84: 757–767.
10. Chao DS, Gorneo JR, Brenman JE, Rialf JA, Peters MF, et al. (1996) Selective loss of sarcomemal neuronal nitric oxide synthase in Becker muscular dystrophy. J Exp Med 184: 699–618.
11. Crosbie RH, Barresi I, Campbell KP (2002) Loss of sarcolemmal nNOS in sarcoglycan-deficient muscle. FASEB J 16: 1786–1791.
12. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, et al. (2000) Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 97: 13018–13023.
13. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JA, et al. (2007) Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS ONE 2: e108.
14. Ouano GL, Gregorevic P, Chamberlain JS (2007) Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta 1772: 243–262.
15. Adams ME, Kramarcy N, Fukuda T, Engel AG, Sealock R, et al. (2004) Structural abnormalities at neuromuscular synapses lacking multiple syntrophin isoforms. J Neurosci 24: 10302–10309.
16. Ameredes BT, Provenzano MA (1999) Influence of nitric oxide on vascular resistance and muscle mechanics during tetanic contractions in situ. J Appl Physiol 87: 142–151.
17. Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV (2001) Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 22: 467–475.
18. Haller RG, Visvim J (2004) in Myology. Engel AG, Franzini-Armstrong C, eds. McGraw Hill. pp 665–680.
19. Chang WJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, et al. (1996) Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A 93: 9412–7.
20. Wehling M, Spencer MJ, Tidball JG (2001) A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 155: 123–131.
21. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG (2005) Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 14: 1921–1933.
22. Brunelli S, Sciorati C, D’Antona G, Innocenzi A, Covarello D, et al. (2007) Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A 104: 264–269.
23. Gregorevic P, Plant DR, Lynch GS (2004) Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle Nerve 3: 295–304.
24. Sockelev R, Irwin B, Dresunderfor H, Bernauer EM (1977) Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil 58: 195–201.
25. Matecki S, Topin N, Hayot M, Rivier F, Echerne B, et al. (2001) A standardized method for the evaluation of respiratory muscle endurance in patients with Duchenne muscular dystrophy. Neuroumuscul Disord 11: 171–177.
26. Watchco JF, O’Day TL, Hoffinan EP (2002) Functional characteristics of dystrophical skeletal muscle: insights from animal models. J Appl Physiol 93: 407–417.
27. Monzegu T, Doriguzzi C, Boneone I, Chiad-Piat L, Hoffinan EP, et al. (2002) Alpha-sarcoglycan deficiency featuring exercise intolerance and myoglobinuria. Neuropediatics: 33: 109–111.
28. Vennere S, Verrrps A, Willeenman MA, ter Laak HJ, Ginajarb IC, et al. (2004) Novel mutations in three patients with LGMD2C with phenotypic differences. Pediatr Neurol 30: 295–304.
29. Huang PL, Dass,on TM, Bredt DS, Snyder SH, Fishman MC (1993) Targeted disruption of the neuronal nitric oxide synthase gene. Cell 73: 1273–1286.
30. Gregorevic P, Allen JM, Mami M, Blankshup MJ, Haraguchi M, et al. (2006) rAAV-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12: 787–789.
31. Yue Y, Liu M, Duan D (2006) C-terminal-truncated microdystrophin recruits dystrobrerin and syndiphon to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. Mol Ther 14: 79–87.

Author Contributions

Conceived and designed the experiments: JP PG SCF. Performed the experiments: JP KNEA. Analyzed the data: JP KNEA PG SCF. Contributed reagents/materials/analysis tools: JSC. Wrote the paper: JP SCF.
